A date for your diary: the next course an “Update on Pharmacoeconomics in the Irish Healthcare Setting” will take place on Friday 21 October 2022 from 9am to 4pm at the Convention Centre Dublin (CCD). Programme Available Registration form 2022
The NCPE recommends that atidarsagene autotemcel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatment*. *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The NCPE recommends that pegvaliase (Palynziq®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.
The NCPE recommends that niraparib (Zejula®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that nivolumab plus ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.
Notice to Applicants: Please refer to updated versions of the Rapid Review Submission Template (v2.2), Applicant Submission Template (v2.1), and the Submission Checklist (v1.4) when making submissions.
The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.
The NCPE recommends that ravulizumab not be considered for reimbursement unless cost effectiveness can be improved relative to comparator treatments*.
The NCPE recommends that vericiguat not be considered for reimbursement*.
The NCPE recommends that ravulizumab (Ultomiris®), for the treatment of adult patients with PNH, be considered for reimbursement provided certain conditions are met.*